In a phase 2 trial investigating the combination of ENA+AZA (which additionally allowed incorporation of VEN and/or a FLT3i as appropriate) in patients with IDH2-mutated ND or R/R-AML, the CR/CRi rate was 58% (N = 11/19) in patients with R/R-AML, with a true CR rate of 26% (N = 5) [64]. This evidence concerns the gene IDH2 and acute myeloid leukemia.